• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of clinexpimmunolLink to Publisher's site
Clin Exp Immunol. Nov 2002; 130(2): 345–351.
PMCID: PMC1906516

Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus

Abstract

To investigate the production mechanism and proinflammatory role of the cytokine interleukin (IL-18) in lupus nephritis, we investigated the plasma concentrations of IL-18 and nitric oxide (NO) and the release of IL-18 and NO from mitogen-activated peripheral blood monomuclear cells (PBMC), in 35 SLE patients with renal disease (RSLE), 37 patients without renal disease (SLE) and 28 sex- and age-matched healthy control subjects (NC). IL-18 and NO concentrations were measured by ELISA and colourimetric non-enzymatic assay, respectively. Gene expressions of IL-18 and IL-18 receptor were analysed by RT-PCR. Plasma IL-18 and NO concentrations were significantly higher in RSLE than NC (both P < 0·01). Elevation of plasma IL-18 in RSLE correlated positively and significantly with SLE disease activity index and plasma NO concentration (r = 0·623, P < 0·0001 and r = 0·455, P = 0·017, respectively), and the latter also showed a positive and significant correlation with plasma creatinine (r = 0·410, P = 0·034) and urea (r = 0·685, P < 0·0001). There was no significant difference in gene expressions of IL-18 and IL-18 receptor in PBMC among RSLE, SLE and NC. Percentage increase in culture supernatant IL-18 concentration was significantly higher in RSLE than SLE and NC (both P < 0·05). The basal NO release was significantly higher in RSLE than that in SLE and NC (both P < 0·005). IL-18 is therefore suggested to play a crucial role in the inflammatory processes of renal disease in SLE.

Keywords: interleukin-18, interleukin-18 receptor, nitric oxide, peripheral blood mononuclear cells, systemic lupus erythematosus

INTRODUCTION

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by the activation of T and polyclonal B lymphocytes, production of autoantibodies, and formation of immune complexes causing tissue and organ damage [1]. In some patients, skin rash and joint pain predominate, while in others glomerulonephritis is the main lesion [1]. The aetiology and pathogenetic mechanisms of this immunological disorder have not been clearly elucidated. Although abnormal production of T helper (Th) cell cytokines [2] and chemokines [3,4] have been implicated, such aberration in SLE is very complex and requires further investigation.

IL-18, formerly called interferon (IFN)-γ-inducing factor, is a proinflammatory cytokine related to the IL-1 family that is produced by Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts and adrenal cortex cells [5]. It plays an important role in the innate immunity and Th1 response to toxic shock and shares functional similarities with IL-12 [5]. Human IL-1 receptor protein is a functional component of the IL-18 receptor [6]. IL-18 receptors are selectively expressed on murine Th1 cells but not Th2 cells [7]. The primary functions of IL-18 include the induction of IFN-γ and TNF-α in T cells and natural killer (NK) cells [8,9], IL-8 in eosinophils [10], up-regulation of Th1 cytokines including IL-2, granulocyte macrophage colony-stimulating factor (GM-CSF) and IFN-γ [5], stimulation of the proliferation of activated T cells [5], and enhancement of Fas ligand expression in NK and cytotoxic T lymphocytes [11]. Elevated IL-18 levels have also been demonstrated in the urine of nephrotic patients [12], serum of patients with multiple sclerosis [13], adult-onset Still's disease [14], type I diabetes mellitus [15], viral infection [16,17], sepsis [18], allergic asthma [19] and inflammatory rheumatic disease [20].

We have recently reported significantly elevated plasma IL-18 concentration in SLE patients compared to controls [21], and the elevation of IL-18 to IL-4 ratio was positively correlated to SLE disease activity index (SLEDAI) [22]. However, the functional role of IL-18 is not well understood. Earlier studies have suggested that increased nitric oxide (NO) and IL-12 production could be important in the pathogenesis of glomerulonephritis in autoimmunity [23]. In an attempt to elucidate the inflammatory role of IL-18 in SLE, we studied the production of IL-18 and NO, and the mRNA expression of IL-18 and IL-18 receptor (R) α, β-chain in patients with or without renal disease. Prompted by the work of Liu and Jones (1998) [24] on the impaired production of IL-12 by peripheral blood mononuclear cells (PBMC), we also investigated the mechanism of in vitro production of IL-18 by PBMC upon their activation with different lymphocyte mitogens including T cell mitogen, phytohaemagglutinin (PHA) and B cell mitogen, lipopolysaccharide (LPS) for understanding the pathogenic role of IL-18.

MATERIALS AND METHODS

SLE patients, control subjects and blood samples

Seventy-two Chinese SLE patients were recruited at the Rheumatology Out-Patient Clinic of the Prince of Wales Hospital, Hong Kong. Diagnosis of SLE was established according to the 1982 revised American Rheumatism Association criteria (ARA) [25], and disease activity evaluated by the SLEDAI [26]. The SLE patients were divided into two groups: 35 SLE patients with renal disease (RSLE group) and 37 SLE patients without renal disease (SLE group). Twenty-eight sex- and age-matched healthy Chinese volunteers were recruited as controls (NC). Twenty ml of heparinized venous peripheral blood were collected from each patient and control subject. The above protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong and informed consent was obtained from all participants.

Whole blood assay (WBA)

The method of Viallard et al. [27] was adopted. After a maximum storage period of 1 h of collected heparinized blood at room temperature, blood was diluted 1 : 1 with RPMI 1640 (Gibco Laboratories, NY, USA), and 1 ml aliquots were deposited in each well of a 24-well plate (Nalge Nunc International, IL, USA). The blood culture was then incubated with or without phytohaemagglutinin (PHA) (Sigma Co., MO, USA) at 5 µg/ml and lipopolysaccharide (LPS) at 25 µg/ml (Sigma) for 24 h at 37°C in a 5% CO2 atmosphere. After incubation, the cell-free supernatant was harvested and stored at −70°C until enzyme-linked immunosorbent assay (ELISA). The percentage (%) increase of IL-18 release from PBMC of each group after the incubation with PHA and LPS was calculated as follows:

[(treatment  control)/control]×100%.

IL-18 assays

Plasma and culture supernatant bioactive IL-18 concentrations of SLE patients and control subjects were measured by ELISA using human IL-18 ELISA kit of Medical & Biological Laboratories Co Ltd, Nagoya, Japan.

Assay for NO

Plasma NO in SLE patients and control subjects were measured in terms of nitrite concentrations as NO is rapidly converted to nitrites and nitrates. A colourimetric non-enzymatic assay kit (Oxford Biomedical Research Inc., MI, USA) was used for measuring the concentrations of total nitrite in plasma and culture supernatant. Briefly, samples were deproteinized by precipitation in zinc sulphate. After centrifugation, the supernatants and the nitrite standards were mixed overnight with 0·5 g granular cadmium beads for reduction of nitrate to nitrite. Following removal of cadmium beads, the supernatants were mixed with the Griess reagent in a 96-well flat-bottomed microtitre plate and the absorbance of developed colour was measured at 540 nm with a microtiter plate reader.

Reverse transcription-polymerase chain reaction (RT-PCR)

PBMC were isolated from heparinzed venous blood for each subject by Ficoll-Paque density gradient centrifugation (Amersham Pharmacia Biotech Ltd, Uppsala, Sweden). Total RNA from PBMC was extracted using RNeasy Mini Kit (QiagenGmbH, Hilden, Germany) according to the manufacturer's instructions. Extracted RNA was reverse transcribed into first-stand complementary DNA using first-strand cDNA Synthesis Kit (Amersham and Pharmacia Biotech). PCR was performed in a reaction mixture containing 3 mm MgCl2, 250 µm dNTPs, 2 units of AmpliTaq Gold DNA polymerase (Perkin Elmer, CA., USA), 50 pmol of 5′ and 3′ primers (Gibco) in PCR reaction buffer for 33 cycles (94°C for 1 min, 60°C for 1 min, and 72°C for 1 min) after an initial 12 min of denaturation at 94°C. All RT-PCR were performed in the linear range of the PCR reaction according to the preliminary experiment. PCR Primers were as the following: IL-18 sense, 5′-AGCTCGGGATCCATGTACTTTGGCAAGCTTGAATCT AAATTATCA-3′ and antisense, 5′-ACTGAATTCCTAGTCT TCGTTTTGAACAGTGAACATTATAGA-3′, yielding a 494-bp product [28]; IL-18 Rα sense, 5′-CCCAACGATAAAGAA GAACGCC-3′ and antisense, 5′-TGTCTGTGCCTCCCGTG CTGGC-3′, yielding a 419-bp product [9]; IL-18 Rβ sense, 5′-AACACAACCCAGTCCGTCCAA-3′ and antisense, 5′-AACATCAGGAAATAGGCTCAG-3′, yielding a 291-bp product [9]; β-actin sense, 5′-AGCGGGAAATCGTGCGTG-3′ and antisense, 5′-CAGGGTACATGGTGGTGCC-3′, yielding a 300-bp product [29]. After the amplification reaction using PTC-200 DNA EngineTM (MJ Research, Inc., MA, USA), PCR products were electrophoresed on 2% agarose gel in TAE buffer (pH 8·0) and stained with ethidium bromide. The electrophorectic bands were documented with Gene Genius Gel Documentation System (Syngene Inc., Cambridge, UK) and intensities of PCR band quantified using Bio-Rad Quantity OneTM software (Bio-Rad Laboratories, CA, USA). The ratio between intensities of PCR bands of IL-18, IL-18 Rα, β and their corresponding β-actin was calculated and expressed as relative intensity of mRNA expression.

Statistical analysis

Because IL-18 and NO concentrations were not in a Gaussian distribution, the Mann–Whitney rank sum test was used to assess their differences between patient and control groups. The Spearman's rank correlation test was used to ascertain the correlations between plasma IL-18, NO and SLEDAI. Results were expressed as median (interquartile range) or mean ± standard deviation (s.d.) as appropriate. All analyses were performed using the statistical package for the Social Sciences (SPSS) statistical software for Windows, Version 9·0 (SPSS Inc., IL, USA). A probability (P) < 0·05 was considered as significantly different.

RESULTS

SLE patients and control subjects

The age, sex, SLEDAI score, duration of diagnosis, serum creatinine and urea and drug treatment of the study populations are summarized in Table 1. Thirty-five SLE patients with renal diseasse (RSLE: 34 females and one male, mean ± s.d. age of 39·1 ± 10·1 years, range 20–59) and 37 SLE patients (SLE: 37 females, 39·3 ± 10·8 years, range 20–67) were recruited. The mean duration of the diagnosis of SLE at the time when patients were evaluated for this study was 12·4 ± 6·3 years (range 1·7–26·6) and 9·0 ± 6·8 years (range 0·3–25·6 years) for RSLE and SLE patients, respectively. The SLEDAI scores of RSLE and SLE patients were 7·9 ± 5·9 (range 0–20) and 2·8 ± 5·6 (range 0–32), respectively. The mean ± s.d. serum creatinine concentrations of RSLE and SLE patients were 105·2 ± 73·0 and 68·2 ± 11·7 µmol/l (normal range: 44–107), P < 0·05, and corresponding serum urea concentrations 8·5 ± 5·7 and 4·7 ± 1·3 mmol/l (normal range 3·4–8·9), P < 0·0001. Twenty-eight healthy control subjects (NC: 27 females and one male, aged 38·5 ± 7·9 years, range 22–51) were recruited. There was no significant difference among the ages of the RSLE or SLE patients and NC subjects (all P > 0·05), and all the three groups were sex-matched.

Table 1
Characteristics of RSLE, SLE patients and control subjects

Plasma concentrations of IL-18 and NO

Plasma concentrations of cytokine IL-18 was significantly higher in RSLE and SLE than NC [median (interquartile range): RSLE 203·8 (143·7–392·3) and SLE 207·9 (119·8–271·1) versus NC 127·0 (82·6–195·2) pg/ml, both P < 0·01]. There was significant and positive correlation between IL-18 concentration and SLEDAI score in RSLE patients (r = 0·623, P < 0·0001) (Fig. 1a). However, no significant correlation was observed between IL-18 concentration and SLEDAI score in SLE patients (r = 0·251, P = 0·135) (Fig. 1b). Plasma NO concentration was significantly higher in RSLE patients than NC [291·2 (183·4–465·4) versus 172·7 (105·1–249·7) µm, P = 0·009], but no significant difference was found between SLE and NC (P = 0·075). In RSLE, plasma IL-18 concentration correlated significantly with plasma NO concentration (r = 0·455, P = 0·017), and the latter also showed a positive and significant correlation with plasma creatinine (r = 0·410, P = 0·034) and urea (r = 0·685, P < 0·0001).

Fig. 1
Correlation between plasma IL-18 concentration and SLEDAI of (a) RSLE and (b) SLE patients. (a) r = 0·623; P < 0·001. (b) r = 0·251; P = 0·135.

In vitro IL-18 and NO production using WBA

In the absence of PHA and LPS stimulation, the spontaneous in vitro production of IL-18 from PBMC was similar in groups of RSLE, SLE patients and NC (P > 0·05). After 24 h incubation with PHA and LPS, culture supernatant IL-18 concentrations was significantly elevated in RSLE (P = 0·03), SLE (P = 0·004) and NC (P = 0·027) compared to medium control (Fig. 2a). The percentage increase in culture supernatant IL-18 level of RSLE was significantly higher than that of SLE and NC [RSLE 93·6 (45·5–171·1) versus SLE 39·2 (15·3–106·5), P = 0·031; and NC 43·8 (27·2–88·6) pg/ml, P = 0·013] (Fig. 2b). As shown in Fig. 3, basal NO release of PBMC in RSLE was significantly higher than that of SLE and NC [RSLE 425·6 (412·8–443·7) versus SLE 386·6 (363·3–423·8), P = 0·005; RSLE 425·6 (412·8–443·7) versus NC 385·6 (355·5–409·8) µm, P = 0·0002]. However, PHA and LPS did not show any significant effect on NO release from all three groups (data not shown).

Fig. 2
IL-18 release from PBMC of RSLE, SLE patients and NC. (a) Supernatant IL-18 concentrations in PBMC culture without or with PHA (5 µg/ml) and LPS (25 µg/ml) for 24 h; (b) % increase of IL-18 release from PBMC after the incubation with PHA ...
Fig. 3
NO release from PBMC of RSLE, SLE patients and NC after 24 h culture.

RT-PCR of IL-18 and IL-18 receptor α and β

PBMC from all subjects were found positive for the expressions of IL-18 and IL-18Rα, β. As shown in Figs 4 and and5,5, there was no significant difference of gene expressions for IL-18 and IL-18 Rα, β in PBMC among groups of RSLE, SLE and NC (all P > 0·05).

Fig. 4
Representative results for the mRNA expression of IL-18, IL-18 Rα, β in PBMC from RSLE, SLE and NC using semiquantitative RT-PCR. PBMC was purified from heparinized blood from subjects and total RNA was extracted, reverse transcribed and ...
Fig. 5
Expression of mRNA of IL-18, IL-18 Rα, β in PBMC from RSLE, SLE and NC using semiquantitative RT-PCR. PBMC was purified from heparinized blood from subjects and total RNA was extracted, reverse transcribed and analysed by PCR as described. ...

DISCUSSION

It has been suggested that SLE is a Th2-polarized disease because of its production of autoantibodies specific for self-antigens [30]. However, other studies have demonstrated that serum cytokines for Th1 response including IL-12 [31], TNF-α [32] and IFN-γ [33] were also significantly higher in SLE patients. Our previous studies have demonstrated that SLE patients exhibited significantly higher plasma concentrations of proinflammatory cytokine IL-12, IL-17 and IL-18, and Th2 cytokine IL-4 [21,22]. Using MRL/lpr mice with spontaneous lupus-like autoimmune disease, it was shown that daily injection of IL-18 or IL-18 plus IL-12 resulted in accelerated protienuria, glomerulonephritis and raised levels of proinflammatory cytokines in MRL/lpr mice [34]. Therefore, IL-18 is suggested to be an important mediator of lupus-like disease including lupus nephritis. SLE patients with diffuse proliferative lupus nephritis also showed the predominance of Th1 immune response and the peripheral blood Th1 to Th2 ratio could be useful as a parameter that reflects the renal histological activity [35].

Our present results demonstrated that the elevation of plasma IL-18 level correlated positively with NO and SLEDAI in SLE patients with renal disease, but not in patients without renal disease. These further indicate that IL-18 played an inflammatory role in glomerulonephritis of SLE patients. As also observed by us, the plasma IL-18 concentrations in RSLE and SLE patients did not show any correlations with the dosages of prednisolone, hydroxychloroquine, azathioprine and cyclosporin A. The mechanistic investigation of IL-18 production by PBMC was studied using WBA, which can preserve better the natural environment and constitute an appropriate milieu for studying production of in vitro cytokines [27]. It also preserves the natural intercellular interactions and circulating stimulatory and inhibitory mediators, including soluble receptors that are present at their physiological concentrations. Our finding of significant increase in IL-18 release from culture supernatant of RSLE but not SLE and NC points to a heightened IL-18 secretory capability of PBMC of RSLE patients. This further strengthens that IL-18 is an important inflammatory mediator in SLE with renal disease.

Using RT-PCR, all PBMC of RSLE, SLE and NC groups showed similar levels for the expressions of IL-18 and IL-18 Rα and β (Figs 4 and and5).5). Although the gene expression of IL-18 Rβ but not IL-18Rα in lymph node cells of MRL lpr/lpr mice has been shown to be increased comparing with non-lupus mice [36], the discrepancy between the animal study and ours may be due to the different characteristics of murine lymph node cells and human PBMC in these two studies. Moreover, the SLE patients in our study exhibited a wide range of SLEDAI while MRL lpr/lpr mice may have a more homogeneous disease activity. Nevertheless, continued expression of IL-18Rα, β in PBMC (Figs 4 and and5)5) suggested that the Th1 cells and NK cells could be activated by the elevated IL-18 to trigger inflammatory response in SLE patients. Although plasma IL-18 level was significantly higher in SLE and RSLE than NC, gene expression of IL-18 was similar between patients and NC (Figs 4 and and5).5). As our ELISA measured only the active form of IL-18 but not the inactive pro-IL-18, the discrepancy between results of ELISA and RT-PCR of IL-18 may be due to the similar level of gene expression of inactive pro-IL-18 in all three groups but up-regulated post-translational cleavage of inactive pro-IL-18 by caspase-1 in PBMC of SLE and RSLE. Therefore, the intracellular activity of caspase-1 should be investigated further in PBMC from control and SLE patients with or without renal disease. In our study of patients with rheumatoid arthritis, we also could not detect any significant change in expressions of IL-18 and IL-18 receptors in PBMC compared with normal control using RT-PCR and cDNA expression array (data not shown). However, PBMC is a mixture of various types of T cells, monocytes, macrophages and granulocytes. The present RT-PCR analysis of IL-18 and IL-18 receptors cannot illustrate the change of gene expression of individual cell types. Therefore, further experiments using purified cell types (e.g. T helper cells, macrophages, etc.) are required.

A previous study has showed that IL-18 accelerates spontaneous autoimmune disease with characteristic glomerulonephritis and vasculitis [34]. The inflammation is exacerbated further by the synergistic action of elevated IL-12 and IL-18 in SLE patients [21,22]. Our present data also revealed that the plasma NO concentration was significantly higher in SLE patients with renal disease. Moreover, we observed that plasma concentrations of IL-18 correlated significantly with plasma NO and the latter showed a positive correlation with plasma creatinine and urea in RSLE. Excessive NO production may play a pivotal role in the pathogenesis of renal disease in SLE. In murine models, NO was found to be related in the pathogenesis of arthritis and glomerulonephritis [37,38]. Elevated production of NO has also been documented in rheumatoid arthritis [39,40] and SLE patients [41,42]. Up-regulated expression of inducible NO synthase (iNOS) was found in the kidneys of patients with active glomerulonephritis, including those with lupus [41]. It is therefore possible that pathogenesis may first involve IL-18 and IL-12 promoting Th1 cell activation, which augments Th1 cytokine IFN-γ production, thereby inducing the expression of NO synthease and the production of NO that mediate glomerulonephritis and vasculitis [43]. Accordingly, our present study should also suggest that IL-18 may serve as a potential target for treatment of autoimmune diseases, including SLE.

Acknowledgments

This study was supported by a Direct Grant for Research of The Chinese University of Hong Kong and a donation from Zindart (De Zhen) Foundation Ltd, Hong Kong.

REFERENCES

1. Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. 3. London: Academic Press; 1999. pp. 1–11.
2. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol. 1999;19:57–66. [PubMed]
3. Kaneko H, Ogasawara H, Naito T, et al. Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol. 1999;26:568–73. [PubMed]
4. Perez de Lema G, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001;12:1369–82. [PubMed]
5. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103:11–24. [PubMed]
6. Torigoe K, Ushio S, Okura T, et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem. 1997;272:25737–42. [PubMed]
7. Xu D, Chan WL, Leung BP, et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med. 1998;188:1485–92. [PMC free article] [PubMed]
8. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest. 1998;101:711–21. [PMC free article] [PubMed]
9. Tanaka M, Harigai M, Kawaguchi Y, et al. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. J Rheumatol. 2001;28:1779–87. [PubMed]
10. Wang W, Tanaka T, Okamura H, et al. Interleukin-18 enhances the production of interleukin-8 by eosinophils. Eur J Immunol. 2001;31:1010–6. [PubMed]
11. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper cells. Cell Immunol. 1996;173:230–5. [PubMed]
12. Matsumoto K, Kanmatsuse K. Elevated interleukin-18 levels in the urine of nephrotic patients. Nephron. 2001;88:334–9. [PubMed]
13. Nicoletti F, Di Marco R, Mangano K, et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology. 2001;57:342–4. [PubMed]
14. Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum. 2001;44:1716–7. [PubMed]
15. Nicoletti F, Conget I, Di Marco R, et al. Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. Diabetologia. 2001;44:309–11. [PubMed]
16. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J Virol. 2001;75:6705–9. [PMC free article] [PubMed]
17. Pirhonen J. Regulation of IL-18 expression in virus infection. Scand J Immunol. 2001;53:533–9. [PubMed]
18. Elsner J, Hochstetter R, Kimmig D, Kapp A. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol. 1996;26:1919–25. [PubMed]
19. Wong CK, Ho CY, Ko FWS, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001;125:177–83. [PMC free article] [PubMed]
20. McInnes IB, Gracie JA, Liew FY. Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis Rheum. 2001;44:1481–3. [PubMed]
21. Wong CK, Li EK, Ho CY, Lam CWK. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatol. 2000;39:1078–81. [PubMed]
22. Wong CK, Ho CY, Li EK, Lam CWK. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000;9:589–93. [PubMed]
23. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-l-arginine. J Exp Med. 1994;179:651–60. [PMC free article] [PubMed]
24. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-γ and negatively with disease activity in SLE. Cytokines. 1998;10:148–53. [PubMed]
25. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7. [PubMed]
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The Committee on Prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40. [PubMed]
27. Viallard JF, Pellegrin JL, Ranchin V, et al. Th1 (IL-2, interferon-gamma (IFN-gamma) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE) Clin Exp Immunol. 1999;115:189–95. [PMC free article] [PubMed]
28. Moller B, Kukoc-Zivojnov N, Kessler U, et al. Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatol. 2001;40:302–9. [PubMed]
29. Wong CK, Ho CY, Lam CW, Zhang JP, Hjelm NM. Differentiation of a human eosinophilic leukemic cell line, EoL-1: characterization by the expression of cytokine receptors, adhesion molecules, CD95 and eosinophilic cationic protein (ECP) Immunol Lett. 1999;68:317–23. [PubMed]
30. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med. 1993;177:1367–81. [PMC free article] [PubMed]
31. Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) – relation to Th1- and Th2-derived cytokines. Clin Exp Immunol. 1999;116:169–73. [PMC free article] [PubMed]
32. Davas EM, Tsirogianni A, Kappou I, et al. Serum IL-6, TNF alpha, p55 srTNF alpha, p75 srTNF alpha, srIL-12 alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol. 1999;18:17–22. [PubMed]
33. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic disease. J Clin Immunol. 1993;13:58–67. [PubMed]
34. Esfandiari E, McInnes IB, Lindop G, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol. 2001;167:5338–47. [PubMed]
35. Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44:2097–106. [PubMed]
36. Neumann D, Del Giudice E, Ciaramella A, Boraschi D, Bossu P. Lymphocytes from autoimmune MRL lpr/lpr mice are hyperresponsive to IL-18 and overexpress the IL-18 receptor accessory chain. J Immunol. 2001;166:3757–62. [PubMed]
37. Oates JC, Ruiz P, Alexander A, Pippen AAM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997;83:86–92. [PubMed]
38. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med. 1994;179:651–60. [PMC free article] [PubMed]
39. Farrel AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis. 1992;51:1219–22. [PMC free article] [PubMed]
40. Miesel R, Zuber M. Reactive nitrogen intermediates, and anti-nuclear antibodies and copper-threonine in serum of patients with rheumatic diseases. Rheumatol Int. 1993;12:95–102. [PubMed]
41. Belmont HM, Levartovshy D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:1810–6. [PubMed]
42. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999;26:318–24. [PubMed]
43. Huang FP, Feng GJ, Lindop G, Stott DI, Liew FY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med. 1996;183:1447–59. [PMC free article] [PubMed]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...